HER2 can activate the SHCBP1-PLK1-MISP signaling pathway, promote cell mitosis, reduce the sensitivity of HER2-positive GC cells to Trastuzumab, and TFBG sensitizes GC to Trastuzumab treatment by blocking the SHCBP1-PLK1-MISP axis (168). The gene discussed is MISP; the disease is gastric cancer.